Advice

in the absence of a submission from the holder of the marketing authorisation:

lenalidomide (Revlimid®) is not recommended for use within NHSScotland.

Indication under review: as combination therapy with bortezomib and dexamethasone for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.  Note: SMC advice 1096/15 is still valid.

Download detailed advice358KB (PDF)

Download

Medicine details

Medicine name:
lenalidomide (Revlimid)
SMC ID:
SMC2217
Indication:

As combination therapy with bortezomib and dexamethasone for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.

Pharmaceutical company
Celgene Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Non submission
Status
Not recommended
Date advice published:
12 August 2019